Show simple item record

dc.contributor.authorKorpisalo, P
dc.contributor.authorKarvinen, H
dc.contributor.authorRissanen, T T
dc.contributor.authorKilpijoki, J
dc.contributor.authorMarjomäki, Varpu
dc.contributor.authorBaluk, P
dc.contributor.authorMcDonald, D M
dc.contributor.authorCao, Y
dc.contributor.authorEriksson, U
dc.contributor.authorAlitalo, K
dc.contributor.authorYlä-Herttuala, S
dc.date.accessioned2019-09-23T11:15:43Z
dc.date.available2019-09-23T11:15:43Z
dc.date.issued2008fi
dc.identifier.citationKorpisalo, P., Karvinen, H., Rissanen, T. T., Kilpijoki, J., Marjomäki, V., Baluk, P., . . . Ylä-Herttuala, S. (2008). Vascular endothelial growth factor-A and platelet-derived growth factor-B combination gene therapy prolongs angiogenic effects via recruitment of interstitial mononuclear cells and paracrine effects rather than improved pericyte coverage of angiogenic vessels. <em>Circulation research</em>, 103, 1092-1099. <a href="https://doi.org/10.1161/CIRCRESAHA.108.182287">https://doi.org/10.1161/CIRCRESAHA.108.182287</a>fi
dc.identifier.otherTUTKAID_31906
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/65611
dc.description.abstractVessel stabilization and the inhibition of side effects such as tissue edema are essential in angiogenic gene therapy. Thus, combination gene transfers stimulating both endothelial cell and pericyte proliferation have become of interest. However, there is currently little data to support combination gene transfer in large animal models. In this study, we evaluated the potential advantages of such a strategy by combining the transfer of adenoviral (Ad) vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF)-B into rabbit hindlimb skeletal muscle. AdLacZ alone or in combination with AdVEGF-A were used as controls. Contrast-enhanced ultrasound, modified Miles assay, and immunohistology were used to quantify perfusion, vascular permeability, and capillary size, respectively. Confocal microscopy was used in the assessment of pericyte-coverage. The transfer of AdPDGF-B alone and in combination with AdVEGF-A induced prominent proliferation of α-smooth muscle actin–, CD31-, RAM11-, HAM56-, and VEGF- positive cells. Although, pericyte recruitment to angiogenic vessels was not improved, combination gene transfer induced a longer-lasting increase in perfusion in both intact and ischemic muscles than AdVEGF-A gene transfer alone. In conclusion, intramuscular delivery of AdVEGF-A and AdPDGF-B, combined, resulted in a prolonged angiogenic response. However, the effects were most likely mediated via paracrine mechanisms rather than an increase in vascular pericyte coverage.fi
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.relation.ispartofseriesCirculation research
dc.rightsIn Copyright
dc.subject.otherkasvutekijäfi
dc.subject.othergeeniterapiafi
dc.subject.othergrowth factorfi
dc.subject.othergene therapyfi
dc.titleVascular endothelial growth factor-A and platelet-derived growth factor-B combination gene therapy prolongs angiogenic effects via recruitment of interstitial mononuclear cells and paracrine effects rather than improved pericyte coverage of angiogenic vesselsfi
dc.typearticle
dc.identifier.urnURN:NBN:fi:jyu-201909114120
dc.contributor.laitosBio- ja ympäristötieteiden laitosfi
dc.contributor.laitosThe Department of Biological and Environmental Scienceen
dc.contributor.oppiaineSolu- ja molekyylibiologia
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.date.updated2019-09-11T12:15:50Z
dc.description.reviewstatuspeerReviewed
dc.format.pagerange1092-1099
dc.relation.issn0009-7330
dc.relation.volume103
dc.type.versionacceptedVersion
dc.rights.copyright© 2008, Wolters Kluwer Health
dc.rights.accesslevelopenAccessfi
dc.format.contentfulltext
dc.rights.urlhttp://rightsstatements.org/page/InC/1.0/?language=en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

In Copyright
Except where otherwise noted, this item's license is described as In Copyright